Sarcopenia Musculoskeletal Diseases
Conditions
Interventions
Participants will participate in a 12-week training protocol (three training sessions per week) in which they train the lower and upper body. In addition, participants are randomly divided into two gr
Sponsors
McMaster University
Eligibility
Sex/Gender
All
Age
60 Years to 85 Years
Inclusion criteria
Inclusion criteria: Current participant inclusion criteria as of 04/04/2024: 1. Male or female, between the ages of 60-85 years, inclusive 2. Willing and able to provide informed consent 3. Be in general good health meaning that the participant doesn’t have any conditions that could pose a risk when performing the measurements (determined by a medical questionnaire and according to the results of several physical performance tests) 4. Non-smoking 5. Have a body mass index (BMI) between 25-40 kg/m² (inclusive) 6. Be able to carry out normal daily living activities and not engage in an exercise training program or diet 7. Not currently taking any protein or weight loss supplements or medications known to affect protein metabolism (i.e., glucocorticoids) Previous participant inclusion criteria: 1. Male or female, between the ages of 60-80 years, inclusive 2. Willing and able to provide informed consent 3. Be in general good health meaning that the participant doesn’t have any conditions that could pose a risk when performing the measurements (determined by a medical questionnaire and according to the results of several physical performance tests) 4. Non-smoking 5. Have a body mass index (BMI) between 25-40 kg/m² (inclusive) 6. Be able to carry out normal daily living activities and not engage in an exercise training program or diet 7. Not currently taking any protein or weight loss supplements or medications known to affect protein metabolism (i.e., glucocorticoids)
Exclusion criteria
Exclusion criteria: Current participant exclusion criteria: 1. Use of tobacco or related products 2. Vegan or vegetarian diet 3. Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements 4. Use assistive walking devices (e.g., cane or walker) 5. History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ, with no significant progression over the past 2 years 6. Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, metabolic/endocrine disorders, or other diseases that would preclude oral protein supplement ingestion and/or assessment of safety and study objectives (except for drug-treated stage 1 or 2 hypertension) 7. Any cachexia-related condition (e.g., relating to cancer, tuberculosis, or human immunodeficiency virus infection and acquired immune deficiency syndrome) or any genetic muscle diseases or disorders 8. Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing) 9. Hypersensitivity or known allergy to any of the components in the test formulations 10. Excessive alcohol consumption (>21 units/week for men and >14 units/week for women) 11. History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anticoagulation therapy (up to 81mg of baby aspirin per day taken as a prophylactic is permitted) 12. Personal or family history of a clotting disorder or deep vein thrombosis 13. Routine/daily usage of non-steroidal anti-inflammatory drugs (NSAIDs, prescription use or daily use of over-the-counter medication), use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), any anabolic steroid, creatine, whey protein supplements, casein or branched-chain amino acids (BCAAs) within 45 days prior to screening 14. Type 2 diabetics Previous participant exclusion criteria: 1. Use of tobacco or related products 2. Vegan or vegetarian diet 3. Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements 4. Use assistive walking devices (e.g., cane or walker) 5. History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ, with no significant progression over the past 2 years 6. Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, metabolic/endocrine disorders, or other diseases that would preclude oral protein supplement ingestion and/or assessment of safety and study objectives (except for drug-treated stage 1 or 2 hypertension) 7. Any cachexia-related condition (e.g., relating to cancer, tuberculosis, or human immunodeficiency virus infection and acquired immune deficiency syndrome) or any genetic muscle diseases or disorders 8. Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing) 9. Hypersensitivity or known allergy to any of the components in the test formulations 10. Excessive alcohol consumption (>21 units/week for men and >14 units/week for women) 11. History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anticoagulation therapy (up to 81mg of baby aspirin per
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lean body mass measured using dual-energy X-ray absorptiometry (DEXA) at week 0 and week 12, pre- and post-training protocol | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 04/04/2024: 1. Muscular isometric strength measured using biodex at week 0 and week 12, pre- and post-training protocol 2. Physical function measured using several physical function tests such as the chair-stand test at week 0 and week 12, pre- and post-training protocol 3. Glycemic control measured using an oral glucose tolerance test at week 0 and week 12, pre- and post-training protocol 4. Muscle protein synthesis rate measured using deuterated water at week 0 and week 12, pre- and post-training protocol Previous secondary outcome measures: 1. Muscular isometric strength measured using biodex at week 0 and week 12, pre- and post-training protocol 2. Physical function measured using several physical function tests such as the chair-stand test at week 0 and week 12, pre- and post-training protocol 3. Aerobic capacity measured using VO2peak test at week 0 and week 12, pre- and post-training protocol 4. Glycemic control measured using oral glucose tolerance test at week 0 and week 12, pre- and post-training protocol 5. Muscle protein synthesis rate measured using deuterated water at week 0 and week 12, pre- and post-training protocol | — |
Countries
Canada
Outcome results
None listed